

Insulin glargine 300 safe, effective in seniors with T2DM

June 26 2018



(HealthDay)—For older adults, insulin glargine 300 units/mL (Gla-300)

is safe and as effective as Gla-100, with a similarly low or lower risk of symptomatic hypoglycemia, according to a study published online June 12 in *Diabetes Care*.

Robert Ritzel, M.D., from Städtisches Klinikum München GmbH in Munich, Germany, and colleagues conducted a multicenter trial involving [older adults](#), aged ≥ 65 years, designed to have about 20 percent of participants be aged ≥ 75 years. A total of 1,014 participants were randomly allocated to receive Gla-300 or Gla-100, titrated to a fasting self-monitored plasma glucose of 5 to 7.2 mmol/L.

The researchers found that from baseline to week 26, the reductions in HbA1c were comparable for Gla-300 and Gla-100 in the overall population and for participants aged ≥ 75 years. Similar and low incidence and rates of confirmed or severe hypoglycemia events were reported between the groups, with lower rates of documented symptomatic hypoglycemia with Gla-300. Compared with the overall population, the subgroup aged ≥ 75 years had a more apparent lower risk of hypoglycemia with Gla-300 versus Gla-100. The annualized rates of documented symptomatic [hypoglycemia](#) were significantly lower with Gla-300 (Gla-300, 1.12 versus Gla-100, 2.71; rate ratio, 0.45).

"Gla-300 demonstrated good efficacy and safety in older people with type 2 diabetes, particularly in those of advanced age (≥ 75 years)," the authors write.

Several authors disclosed ties to pharmaceutical companies, including Sanofi, which funded the study and the clinical trial considered in the analysis.

More information: [Abstract/Full Text \(subscription or payment may be required\)](#)

Copyright © 2018 [HealthDay](#). All rights reserved.

Citation: Insulin glargine 300 safe, effective in seniors with T2DM (2018, June 26) retrieved 7 May 2024 from <https://medicalxpress.com/news/2018-06-insulin-glargine-safe-effective-seniors.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.